Stocktoria
Keros Therapeutics, Inc. KROS
Keros Therapeutics, Inc. (KROS) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $244.1M at a 35.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.873 |
| Retained earnings / assets | -1.425 |
| EBIT / assets | 0.2 |
| Equity / liabilities | 8.688 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | 6/9 | 11.55 | 2.5 | — |
| RCUS | Arcus Biosciences, Inc. | — | -0.75 | — | -4.3% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
| ANAB | ANAPTYSBIO, INC | 5/9 | -0.3 | — | +157% |
| SDGR | Schrodinger, Inc. | 4/9 | -0.33 | — | +23.3% |
| LFVN | Lifevantage Corp | 6/9 | -0.45 | 8.5 | +14.2% |
| PBYI | PUMA BIOTECHNOLOGY, INC. | 6/9 | -14.13 | 13.3 | -0.9% |
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
FAQ
Is KROS financially healthy?
Keros Therapeutics, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does KROS pay a dividend?
No, Keros Therapeutics, Inc. does not currently pay a dividend.
How profitable is KROS?
In FY2025, Keros Therapeutics, Inc. had a net margin of 35.7% and a return on equity of 28.7%.
What is KROS's P/E ratio?
Keros Therapeutics, Inc.'s trailing price-to-earnings (P/E) ratio is about 2.5×, based on its latest annual earnings.
What is the analyst price target for KROS?
The average Wall-Street price target for Keros Therapeutics, Inc. is $21.83, about 94.9% above the recent price, from 6 analysts.
Is KROS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Keros Therapeutics, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 2.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.